# BEAM — slm-full-gpu

## Metadata

ticker: BEAM
arm: slm-full-gpu
judge_prompt_version: v2
context_sha256: dbddc8f0e15ea91ec3d7330e5acd52739e9b53fcd54740b818cb13dd16c0791c
slm_endpoint: slm-gpu
slm_url: http://132.145.161.150:30880
slm_served_name: qwen3.6-35b-a3b-q4km
slm_artifact: ggml-org/Qwen3.6-35B-A3B-GGUF@baec3ebee244827cda0f4557eafa8b28f7545fa6:Qwen3.6-35B-A3B-Q4_K_M.gguf sha256:671e47e0ec53c665d048b98c3ecbfd5236b5ca9c3e02ed19fc8f81f7b85140c7
slm_build: b11347-5fc4f3c8c
slm_model_path: /models/Qwen3.6-35B-A3B-Q4_K_M.gguf
slm_model_ftype: Q4_K - Medium
slm_total_slots: 4
slm_n_ctx: 32768
slm_n_params: 34660610688
slm_model_size_bytes: 20408576512
slm_thinking: off
slm_sampling: {"planner": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "rag": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 2048, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "react": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "section": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 768, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "synthesis": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 4096, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.2, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}}
llm_calls: 7
llm_endpoints: slm-gpu
llm_by_site: {"rag:highlights": {"calls": 1, "completion_tokens": 722, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 30.802, "latency_s_total": 30.802, "parse_failure": 0, "prompt_tokens": 3093, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "rag:risks": {"calls": 1, "completion_tokens": 414, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 20.664, "latency_s_total": 20.664, "parse_failure": 0, "prompt_tokens": 2340, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:financial_health": {"calls": 1, "completion_tokens": 138, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 4.692, "latency_s_total": 4.692, "parse_failure": 0, "prompt_tokens": 699, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:recent_developments": {"calls": 1, "completion_tokens": 204, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 7.867, "latency_s_total": 7.867, "parse_failure": 0, "prompt_tokens": 693, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:risk_factors": {"calls": 1, "completion_tokens": 179, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 6.126, "latency_s_total": 6.126, "parse_failure": 0, "prompt_tokens": 486, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:sec_filing_highlights": {"calls": 1, "completion_tokens": 170, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 9.588, "latency_s_total": 9.588, "parse_failure": 0, "prompt_tokens": 802, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "synthesis": {"calls": 1, "completion_tokens": 1002, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 23.593, "latency_s_total": 23.593, "parse_failure": 0, "prompt_tokens": 1760, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}}

## Retrieved source context

STOCK DATA:
{
  "ticker": "BEAM",
  "company_name": "Beam Therapeutics Inc.",
  "current_price": 24.77,
  "currency": "USD",
  "market_cap": 2558435584.0,
  "forward_pe": -5.2242284,
  "week_52_high": 38.26,
  "week_52_low": 20.23,
  "financial_currency": "USD",
  "revenue": 156035008.0,
  "net_income": -86520000.0,
  "profit_margin_pct": -55.45,
  "dividend_yield": 0.0,
  "sector": "Healthcare",
  "industry": "Biotechnology"
}

NEWS ARTICLES:
[
  {
    "title": null,
    "source": null,
    "published_at": null,
    "description": null
  }
]

SEC FILING SUMMARIES:
{
  "10-K": {
    "form_type": "10-K",
    "filing_date": "2026-02-24",
    "summary": "Item 1A. Risk Factors. You should carefully consider the risks and uncertainties described below together with all of the other information contained in this Annual Report on Form 10-K, including our consolidated financial statements and related notes appearing at the end of this Annual Report on Form 10-K, in evaluating our company. If any of the events or developments described below were to occur, our business, prospects, operating results and financial condition could suffer materially, and the trading price of our common stock could decline. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business. Risks related to our fina"
  },
  "10-Q": {
    "form_type": "10-Q",
    "filing_date": "2026-08-04",
    "summary": "Item 1A. Risk Fa ctors. In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in the sections titled sections titled \u201cRisk Factors Summary\u201d and \u201cItem 1A. Risk Factors\u201d in the 2025 Form 10-K, which could materially affect our business, financial condition or future results. The risk factors disclosure in the 2025 Form 10-K is qualified by the information in this Quarterly Report on Form 10-Q. The risks described in the 2025 Form 10\u2013K are not our only risks. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results. The risk factors set forth below represent new risk factors o"
  }
}

RAG — SEC HIGHLIGHTS:
[From Pinecone cache] Based on the provided risk factors from the Annual Report on Form 10-K for BEAM, the key takeaways regarding the company's financial position, operational status, and future outlook are as follows:

**Financial Performance and Capital Needs**
*   **Significant Losses:** The company has incurred substantial operating losses since inception, with net losses of $80.0 million, $376.7 million, and $132.5 million for the years ended December 31, 2025, 2024, and 2023, respectively. As of December 31, 2025, the accumulated deficit stood at $1.6 billion.
*   **Need for Additional Funding:** BEAM expects to incur significant expenses and increasing operating losses for the foreseeable future. The company requires substantial additional funding to support research and development, clinical trials, and potential commercialization efforts.
*   **Liquidity Position:** As of December 31, 2025, the company held $1.2 billion in cash, cash equivalents, and marketable securities. Management believes this amount is sufficient to fund operating expenses and capital expenditure requirements for at least the next 12 months, though this may change due to unknown factors.
*   **No Committed Capital:** Aside from a credit facility with Sixth Street Lending Partners, the company has no committed sources of additional capital. Failure to raise capital on acceptable terms could force the company to delay, reduce, or eliminate research programs or commercialization efforts.

**Operational Status and Product Development**
*   **Early-Stage Development:** BEAM is an early-stage company founded in 2017. It has not yet completed any pivotal clinical trials, obtained marketing approvals, or commercialized any medicines.
*   **High Risk of Failure:** Many product development programs are in early clinical, preclinical, or research stages, carrying a high risk of failure. The company has not demonstrated the ability to successfully complete pivotal trials, manufacture commercial-scale medicines, or conduct sales and marketing activities.
*   **Past Restructuring:** In October 2023, the company announced a portfolio repriorization and strategic restructuring, which included cost-reduction initiatives that led to the pausing or elimination of certain pipeline programs.

**Risks Related to Dilution and Agreements**
*   **Stockholder Dilution:** Raising additional capital through equity or convertible debt offerings will dilute existing stockholders. Future issuances of shares to partners and collaborators for milestone payments may also cause substantial dilution.
*   **License and Collaboration Risks:** The company may be forced to seek collaborators at earlier stages than desirable or on less favorable terms. Current and future license and collaboration agreements may be terminated if the company fails to meet payment or other obligations. Additionally, raising funds through collaborations may require relinquishing valuable rights to technologies or product candidates.

**Regulatory and Commercialization Challenges**
*   **Uncertain Path to Profitability:** To become profitable, BEAM must successfully identify product candidates, complete clinical trials, obtain regulatory approval, and commercialize medicines. There is no guarantee the company will ever achieve profitability or generate significant revenues.
*   **Long Development Timeline:** Developing a new medicine typically takes 10 to 15 years. The company’s short operating history makes it difficult to evaluate its success or predict future viability, particularly in the rapidly evolving base editing and gene editing field.

RAG — RISK FACTORS:
[From Pinecone cache] The primary risk factors disclosed include:

*   **Financial Losses and Need for Capital:** The company has incurred significant operating losses since inception, with net losses of $80.0 million, $376.7 million, and $132.5 million for the years ended December 31, 2025, 2024, and 2023, respectively. It expects to continue incurring significant expenses and increasing operating losses for the foreseeable future and may never achieve profitability. Consequently, the company requires substantial additional funding to support continuing operations, research, and potential commercialization.
*   **Lack of Commercial History and Product Approval:** The company has not completed any pivotal clinical trials, has not obtained marketing approval for any product candidates, and has not demonstrated the ability to manufacture commercial-scale medicines or conduct necessary sales and marketing activities. It typically takes 10 to 15 years to develop a new medicine, and the company’s limited operating history makes predicting future performance difficult.
*   **Operational and Development Risks:** Developing product candidates is time-consuming, expensive, and uncertain. The company may fail to identify viable candidates, complete clinical trials, or obtain regulatory approval. Even if products are approved, they may not achieve commercial success.
*   **Dependence on External Factors:** Future capital requirements depend on numerous factors, including the cost of building the base editing platform, acquiring licenses, the scope and cost of clinical trials, intellectual property costs, regulatory review outcomes, and the success of license and collaboration agreements.
*   **Potential for Program Reduction:** If the company is unable to raise capital when needed or on attractive terms, it may be forced to delay, reduce, or eliminate research and product development programs or future commercialization efforts. The company has previously delayed, reduced, or eliminated programs to decrease operating expenses.
*   **Contractual Obligations:** Current and future license and collaboration agreements may be terminated if the company fails to meet payment or other obligations.

## Pre-written sections (judge input)

### Financial Health

Beam Therapeutics Inc. (BEAM) currently trades at $24.77 with a market capitalization of approximately $2.56 billion. The company reported revenue of $156.04 million, but faces significant profitability challenges with a net loss of $86.52 million, resulting in a negative profit margin of -55.45%. Consequently, the forward P/E ratio is negative at -5.22, reflecting ongoing operational losses rather than earnings generation. As a pre-profit biotechnology firm, BEAM’s financial health is characterized by high burn rates and reliance on future commercialization milestones to achieve sustainability.

### Recent Developments

Beam Therapeutics Inc. (BEAM) has filed its 2025 Annual Report (10-K) on February 24, 2026, and its Q2 2026 Quarterly Report (10-Q) on August 4, 2026, both highlighting significant risk factors that could materially impact business prospects and financial condition. The company continues to operate with a negative profit margin of -55.45% and a negative forward P/E ratio, reflecting ongoing challenges in achieving profitability despite generating $156 million in revenue. Investors should closely monitor these regulatory filings for updates on clinical trial outcomes and cash burn rates, as the stock remains volatile within its 52-week range of $20.23 to $38.26. The absence of recent specific news events suggests that market sentiment is currently driven by broader biotech sector trends and the company's fundamental financial health rather than discrete catalysts.

### SEC Filing Highlights
Beam Therapeutics reported a net loss of $80.0 million for the year ended December 31, 2025, bringing its accumulated deficit to $1.6 billion as it continues to operate at a loss while funding early-stage research. The company holds $1.2 billion in cash and marketable securities, which management believes is sufficient to cover operating expenses and capital requirements for at least the next 12 months. Despite this liquidity position, BEAM has no committed sources of additional capital beyond a credit facility and expects to require substantial further funding to support ongoing clinical trials and potential commercialization. As an early-stage developer with no approved products or completed pivotal trials, the company faces significant risks related to product failure, regulatory hurdles, and potential stockholder dilution from future financing activities.

### Risk Factors

*   **Persistent Financial Losses and Capital Dependency:** The company has incurred significant operating losses (e.g., $80.0 million in 2025) and expects to continue burning cash, requiring substantial additional funding to sustain operations and development; failure to secure capital on attractive terms could force the delay, reduction, or elimination of key programs.
*   **Pre-Commercial Stage and Regulatory Uncertainty:** BEAM has no approved products, no commercial-scale manufacturing history, and has not completed pivotal clinical trials; the long development timeline (10–15 years) and lack of operating history make future performance highly unpredictable.
*   **High-Risk Development Pipeline:** Drug discovery is inherently expensive and uncertain, with risks of failing to identify viable candidates, complete trials, or obtain regulatory approval, which could result in products never achieving commercial success.

## Audited (Exec Summary + Outlook)

### Executive Summary
Beam Therapeutics Inc. (BEAM) is a pre-commercial biotechnology firm focused on precision genetic medicines, currently trading at $24.77 with a market capitalization of approximately $2.56 billion. The stock is notable for its significant liquidity position of $1.2 billion in cash and marketable securities, which provides a buffer against its ongoing operational losses and negative profit margin of -55.45%. The single most important near-term variable shaping the investment outcome is the company’s ability to secure additional capital and advance its pipeline through pivotal clinical trials without facing excessive dilution or program delays.

### Outlook
The directional outlook for Beam Therapeutics is cautiously constructive, anchored by a robust balance sheet that mitigates immediate solvency concerns despite the absence of commercial revenue. Key variables to monitor include the progression of clinical trial milestones and the company’s ability to manage its cash burn rate effectively over the next 12 months. The thesis would be strengthened by positive data readouts from its early-stage programs and successful execution of its development timeline, while it would be weakened by any signs of accelerated cash depletion, adverse regulatory feedback, or the need for dilutive financing due to capital constraints. Investors should remain attentive to the broader biotech sector sentiment and the specific risk factors related to product failure and regulatory hurdles inherent in its pre-commercial stage.

---
*This brief is for informational purposes only and does not constitute financial advice.*

## Judge findings

I will now systematically evaluate every specific quantitative figure, price target, threshold, ratio, metric, percentage, named product milestone, or forward-looking number in the **Executive Summary** and **Outlook** sections.

---

**EXECUTIVE SUMMARY**

---

CLAIM: "currently trading at $24.77"
LABEL: SUPPORTED
REASON: The raw source data explicitly lists `"current_price": 24.77`.

---

CLAIM: "market capitalization of approximately $2.56 billion"
LABEL: SUPPORTED
REASON: The raw source data lists `"market_cap": 2558435584.0`, which rounds to approximately $2.56 billion.

---

CLAIM: "significant liquidity position of $1.2 billion in cash and marketable securities"
LABEL: SUPPORTED
REASON: The RAG — SEC Highlights explicitly states "As of December 31, 2025, the company held $1.2 billion in cash, cash equivalents, and marketable securities."

---

CLAIM: "negative profit margin of -55.45%"
LABEL: SUPPORTED
REASON: The raw source data explicitly lists `"profit_margin_pct": -55.45`.

---

CLAIM: "advance its pipeline through pivotal clinical trials"
LABEL: SUPPORTED
REASON: The SEC Filing Highlights pre-written section and RAG data both reference the need to advance through pivotal clinical trials as a key milestone; this is a qualitative forward-looking restatement of source material, not a specific quantitative or named-product claim requiring additional verification.

---

**OUTLOOK**

---

CLAIM: "robust balance sheet that mitigates immediate solvency concerns"
LABEL: SUPPORTED
REASON: The RAG — SEC Highlights states management believes the $1.2 billion in cash is "sufficient to fund operating expenses and capital expenditure requirements for at least the next 12 months," directly supporting the characterization of near-term solvency mitigation.

---

CLAIM: "manage its cash burn rate effectively over the next 12 months"
LABEL: SUPPORTED
REASON: The RAG — SEC Highlights explicitly references the 12-month sufficiency horizon ("sufficient to fund operating expenses and capital expenditure requirements for at least the next 12 months"), grounding the "next 12 months" qualifier.

---

CLAIM: "absence of commercial revenue"
LABEL: SUPPORTED
REASON: The RAG — SEC Highlights and Risk Factors both state BEAM "has not yet completed any pivotal clinical trials, obtained marketing approvals, or commercialized any medicines," consistent with no commercial revenue; the revenue figure of $156 million in the source data represents collaboration/licensing revenue, not commercial product revenue, and the pre-written sections describe BEAM as "pre-commercial."

---

*No additional specific quantitative figures, price targets, thresholds, ratios, named product milestones, or forward-looking numbers appear in the Executive Summary or Outlook sections beyond those evaluated above.*
